Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
Status:
Suspended
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the safety and effectiveness of a drug called apixaban for the
treatment of upper extremity deep vein thrombosis (UEDVT) and clinically important bleeding.
Subjects will receive apixaban 10 mg by mouth twice a day for 7 days, followed by 5 mg by
mouth twice a day for a duration of 11 weeks. There will be a followup visit at 12 weeks for
all participants. A total of 375 are to be enrolled.
The study drug has been approved to treat blood clots. The study drug has not been studied
uniquely for the treatment of blood clots in the upper extremity however. Because it is
unknown whether it is effective to treat blood clots in the upper extremity, the principal
investigator cannot guarantee that there will be benefit to study subjects; however, it is
hoped that the information obtained from this research study will help treat patients in the
future.